Iradimed (IRMD) Form 4: Director awarded 2,095 RSUs with 3-year vesting

Rhea-AI Filing Summary

Joe E. Kiani, a director of Iradimed Corporation (IRMD), received a grant of 2,095 restricted stock units (RSUs) on 09/23/2025 under the companys 2023 Equity Incentive Plan. Each RSU represents a contingent right to one share of common stock and the reporting person is shown as directly owning 2,095 shares following the transaction. The RSUs carry a $0 price and vest in three equal annual installments beginning on 09/23/2026, at which time vested units will convert into an equivalent number of common shares. The Form 4 is signed by Joe E. Kiani on 09/25/2025.

Positive

• Grant of 2,095 RSUs under the 2023 Equity Incentive Plan is disclosed
• Vesting schedule is specified: three equal annual installments beginning 09/23/2026
• RSUs convert to one share per unit, and the filing shows direct beneficial ownership of 2,095 shares following the grant

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Director received 2,095 RSUs under the 2023 plan, vesting over three years, indicating routine equity-based compensation.

The grant is a standard equity award for a director, provided under the companys 2023 Equity Incentive Plan. The award vests in three equal annual installments beginning one year after the grant date, which is common practice to align director incentives with long-term shareholder interests. The Form 4 shows direct beneficial ownership of 2,095 shares post-grant and a $0 per-unit price, consistent with restricted units rather than a purchase transaction. No additional material transactions or disclosures appear in the filing.

Compensation Analyst

TL;DR: Non-cash RSU grant of 2,095 units, standard vesting schedule, no purchase price, routine director compensation.

This transaction reflects issuance of restricted stock units that will convert to common shares upon vesting. The absence of an exercise/strike price and the three-year vesting schedule suggest the award is intended as retention and alignment compensation. The number of units and schedule are disclosed, but the filing does not include aggregate holdings prior to the grant or any value metric, limiting quantitative assessment of compensation scale relative to peers.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

KIANI JOE E

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	09/23/2025		A		2,095		(2)	(2)	Common Stock	2,095	$0	2,095	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

2. The reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on September 23, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

	/s/ Joe E. Kiani	09/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did IRMD director Joe E. Kiani receive on 09/23/2025?

He received 2,095 restricted stock units (RSUs) under Iradimed Corporations 2023 Equity Incentive Plan.

When do the RSUs awarded to Joe E. Kiani vest?

The RSUs vest in three equal annual installments beginning on 09/23/2026.

How many shares will Joe E. Kiani own after the reported transaction for IRMD?

The Form 4 reports 2,095 shares of common stock beneficially owned following the reported RSU grant.

Did Joe E. Kiani pay for the RSUs reported on the Form 4?

No purchase price is reported; the RSUs are shown with a $0 price, consistent with restricted stock units.

When was the Form 4 signed for the IRMD transaction?

The Form 4 is signed by Joe E. Kiani on 09/25/2025.